← Leaderboards
Powell Brown
University Of Tx Md Anderson Can Ctr
$6,526,513
Attributed
$6,526,513
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.1M · FY2011–22$2.5M$1.9M$1.3M$625K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$6,526,513 · 3
By mechanism
N01$6,526,513 · 3
Top collaborators
No co-investigators on record.
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Lanlan Shen$6,924,000
- Beth M Beadle$2,076,341
- Adam Garden$425,629
- Eduardo Vilar Sanchez$16,310,319
- Susan K Peterson$7,271,594
Others in their field
Top investigators on “Preventive”
- Lawrence Corey · Fred Hutchinson Cancer Center$609,181,782
- Jeffrey P Krischer · University Of South Florida$605,511,231
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$530,065,238
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$499,311,118
- David Heimbrook · Leidos Biomedical Research, Inc.$496,394,926
Research focus
PreventiveToxic EffectMalignant NeoplasmsDoseDiagnosisRattusBiological MarkersSafetyDesignClinically RelevantBaseApoptosisPhase I Clinical TrialsClinical TrialsDivision Of Cancer PreventionDimerizationCytokineFamilyCell ProliferationBiologicalAffinityChemopreventive AgentCancer PreventionBinding
Grant awards (6)
TARGETING STAT3 TO PREVENT NON-SMALL CELL LUNG CANCER (NSCLC) IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)$1,097,981
N01 · FY2022 · CA · contact PI
TASK ORDER TITLE: EVALUATION OF REAL-TIME METABOLIC IMAGING BIOMARKERS FOR DETECTION OF PANCREATIC PREMALIGNANT LESIONS$1,166,274
N01 · FY2021 · CA · contact PI
TARGETING STAT3 TO PREVENT COLORECTAL CANCER SECONDARY TO INFLAMMATORY BOWEL DISEASE$932,948
N01 · FY2021 · CA · contact PI
OPTIMIZATION OF DOSING REGIMENS OF SULINDAC IN COMBINATION WITH ERLOTINIB FOR SMALL INTESTINAL AND COLON CANCER PREVENTION$854,290
N01 · FY2019 · CA · contact PI
CORE INFRASTRUCTURE SUPPORT$793,323
N01 · FY2014 · CA · contact PI
Phase 1 and Phase 2 Clinical Trials of Cancer Chemopreventive Agents$1,681,697
N01 · FY2011 · CA · contact PI